ENTRY       D08976                      Drug
NAME        Pomalidomide (JAN/USAN/INN);
            Pomalyst (TN)
PRODUCT     POMALYST (Celgene Corporation)
FORMULA     C13H11N3O4
EXACT_MASS  273.075
MOL_WEIGHT  273.2441
CLASS       Metabolizing enzyme substrate
             DG01892  CYP1A2 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 4291
            ATC code: L04AX06
            Product: D08976<JP/US>
EFFICACY    Antineoplastic, Immunomodulator
  DISEASE   Multiple myeloma [DS:H00010]
COMMENT     Thalidomide [DR:D00754] analog
TARGET      TNF (TNFA, TNFSF2) [HSA:7124] [KO:K03156]
            IL6 [HSA:3569] [KO:K05405]
  PATHWAY   hsa04060(3569+7124)  Cytokine-cytokine receptor interaction
            hsa04210(7124)  Apoptosis
            hsa04640(3569+7124)  Hematopoietic cell lineage
            hsa04650(7124)  Natural killer cell mediated cytotoxicity
            hsa04660(7124)  T cell receptor signaling pathway
            hsa04668(3569+7124)  TNF signaling pathway
METABOLISM  Enzyme: CYP1A2 [HSA:1544], CYP3A4 [HSA:1576]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AX Other immunosuppressants
                 L04AX06 Pomalidomide
                  D08976  Pomalidomide (JAN/USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Immunomodulatory Agents
               Pomalidomide
                D08976  Pomalidomide (JAN/USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D08976  Pomalidomide (JAN/USAN/INN)
            Drug groups [BR:br08330]
             Metabolizing enzyme substrate
              DG01892  CYP1A2 substrate
               D08976  Pomalidomide
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D08976  Pomalidomide
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Interleukins
                IL6
                 D08976  Pomalidomide (JAN/USAN/INN) &lt;JP/US&gt;
               Tumor necrosis factors
                TNF (TNFA, TNFSF2)
                 D08976  Pomalidomide (JAN/USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D08976
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D08976
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D08976
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D08976
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D08976
DBLINKS     CAS: 19171-19-8
            PubChem: 96025659
            ChEBI: 72690
            LigandBox: D08976
ATOM        20
            1   N1y N    26.1800  -16.0300
            2   C1y C    27.5800  -16.0300
            3   C5x C    25.3400  -17.1500
            4   C5x C    25.3400  -14.9100
            5   C5x C    28.2800  -14.7700
            6   C1x C    28.2800  -17.2200
            7   C8y C    24.0100  -16.7300
            8   O5x O    25.8300  -18.4800
            9   C8y C    24.0100  -15.3300
            10  O5x O    25.7600  -13.5800
            11  N1x N    29.6800  -14.7700
            12  O5x O    27.5800  -13.5800
            13  C1x C    29.7500  -17.2200
            14  C8x C    22.8200  -17.4300
            15  C8y C    22.8200  -14.6300
            16  C5x C    30.3800  -15.9600
            17  C8x C    21.6300  -16.7300
            18  C8x C    21.6300  -15.3300
            19  O5x O    31.7800  -15.9600
            20  N1a N    22.8200  -13.2300
BOND        22
            1     1   2 1
            2     1   3 1
            3     1   4 1
            4     2   5 1
            5     2   6 1
            6     3   7 1
            7     3   8 2
            8     4   9 1
            9     4  10 2
            10    5  11 1
            11    5  12 2
            12    6  13 1
            13    7  14 1
            14    9  15 1
            15   11  16 1
            16   14  17 2
            17   15  18 2
            18   16  19 2
            19    7   9 2
            20   13  16 1
            21   17  18 1
            22   15  20 1
///
